研究单位：[1]Chengdu Kanghong Biotech Co., Ltd.[2]Peking Union Medical College Hospital,Beijing,China,100032[3]Peking University Third Hospital,Beijing,China,100083[4]Beijing Tongren hospital affiliated to Capital Medical University,Beijing,China,100730[5]Southwest Hospital,Chongqing,Chongqing,China,400038[6]Daping Hospital, Research Institute of Surgery Third Military Medical University,Chongqing,Chongqing,China,400042[7]Zhongshan Ophthalmic Center,Guangzhou,Guangdong,China,510060[8]Wuhan General Hospital of Guangzhou Military,Wuhan,Hubei,China,430070[9]Wuxi No.2 People's Hospital,Wuxi,Jiangsu,China,214002[10]Ophthalmologic Hospital of Qingdao,Qingdao,Shandong,China,266071[11]Shanghai First People's Hospital,Shanghai,Shanghai,China,200080[12]Xijing Hospital,Xian,Shanxi,China,710032[13]West China Hospital of Sichuan University,Chengdu,Sichuan,China,610041[14]The Affiliated Eye Hospital of WMC,Wenzhou,Zhejiang,China,325027
研究目的：
This study is design to evaluate the effect of conbercept therapy on visual acuity and anatomic outcomes compared to sham injection and durability of response observed in subjects with choroid neovascularization secondary to pathological myopia.
